NBIO — Nascent Biotech Share Price
0.000.00%
Last trade - 00:00- $10.24m
- $9.99m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 502.43 | ||
| Price to Tang. Book | 502.43 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -7345.57% | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 0.75 | 1 | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Nascent Biotech, Inc. is a phase II clinical-stage biopharmaceutical company engaged in developing monoclonal antibodies for the treatment of various cancer types. The Company focuses on biologic drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. It owns a drug candidate, Pritumumab, which the Company is developing as a treatment for epithelial cancers that includes lung, breast, colon, brain, and pancreas. Its initial focus is on patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma. The Company is exploring Pritumumab in its use against viruses. The Company is also engaged in developing a traditional vaccine platform to create vaccines for viral infections.
Directors
- Last Annual
- March 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- May 13th, 2009
- Public Since
- June 6th, 2012
- No. of Shareholders
- 153
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 169,729,565
- Address
- 631 Us Hwy 1, Suite 407, NORTH PALM BEACH, 33408
- Web
- https://www.nascentbiotech.com/
- Phone
- +1 6129615656
- Auditors
- Fruci & Associates II, PLLC
Upcoming Events for NBIO
Q1 2024 Nascent Biotech Inc Earnings Release
Q2 2024 Nascent Biotech Inc Earnings Release
Similar to NBIO
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
What is the Nascent Biotech share price?
As of Today at 22:13 UTC, shares in Nascent Biotech are trading at $0.09. This share price information is delayed by 15 minutes.
How has the Nascent Biotech share price performed this year?
Shares in Nascent Biotech last closed at $0.09 and the price had moved by +81.62% over the past 365 days. In terms of relative price strength the Nascent Biotech share price has outperformed the S&P500 Index by +52.42% over the past year.
What are the analyst and broker recommendations for Nascent Biotech?
There is no consensus recommendation for this security.
What is the Nascent Biotech dividend yield?
Nascent Biotech does not currently pay a dividend.
Does Nascent Biotech pay a dividend?
Nascent Biotech does not currently pay a dividend.
When does Nascent Biotech next pay dividends?
Nascent Biotech does not currently pay a dividend.
How do I buy Nascent Biotech shares?
To buy shares in Nascent Biotech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Nascent Biotech?
As of the previous close price of $0.09, shares in Nascent Biotech had a market capitalisation of $15.26m.
Where are Nascent Biotech shares listed?
Here are the trading details for Nascent Biotech:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: NBIO
What kind of share is Nascent Biotech?
Based on an overall assessment of its quality, value and momentum Nascent Biotech is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Nascent Biotech share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Nascent Biotech share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nascent Biotech. Over the past six months, its share price has underperformed the S&P500 Index by -59.8%.
As of the last closing price of $0.09, shares in Nascent Biotech were trading -29.87% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Nascent Biotech PE Ratio?
The Nascent Biotech PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.09.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Nascent Biotech?
Nascent Biotech's management team is headed by:
- Sean Carrick - PRE
- Lowell Holden - CFO
- Douglas Karas - IND